News

Scientists discovered a long sought-after inhibitor for the DNA repair polymerase, Polθ, which may be key to treating drug-resistant BRCA1 and BRCA2-mutant cancers.

A newly developed drug stabilizes dopamine and serotonin levels using a novel mechanism. It effectively treats psychosis in patients with schizophrenia, and researchers are testing its efficacy for Parkinson’s disease as well.

Researchers plan to monitor the immune responses of COVID-19 patients for one year to see how they correlate with illness severity and lasting effects. This data will help develop personalized treatments for patients.

Scientists identified a new sex-specific pain circuit in the brain, laying the groundwork for developing better pain-relieving drugs for both sexes.

An upcoming clinical study will test whether a B. infantis probiotic can prevent the development of type 1 diabetes in predisposed infants.

Targeting oncogenic transcription factors like MYC is challenging, but researchers found a way to target its regulator, WDR5, for degradation, exemplifying the capacity of protein degraders to target the “undruggable.”

Sævik measures corticosteroid levels in people with Addison’s disease to challenge the pervasive idea that these patients lose all adrenal cortex function as their disease progresses.

Spending an hour every day listening to a low-pitched thrum and gazing at blinking lights may help prevent structural changes in the brain and cognitive impairments associated with Alzheimer’s disease.

The common flu treatment, Tamiflu, may help treat lethal bloodstream staph infections.

A group of researchers leveraged their location to tackle questions about the rare autoimmune disorder, Addison’s disease.